SyrSpend� SF Compatibility table
www.fagron.com SyrSpend� SF Compatibility table
SyrSpend� SF SyrSpend� SF SyrSpend� SF PH4 Liquid PH4 Dry ALKA Dry (PRESERVED) (UNPRESERVED) (UNPRESERVED)
Physical and Physical Physical Active pharmaceutical Ingredient (API) Concentration chemical Storage and chemical and chemical Storage stability (days) stability (days) stability (days)
16 Acetaminophen (paracetamol) 50 mg/mL 90
21 Acetazolamide 25 mg/mL 90
16 Allopurinol 20 mg/mL 90
20 Alprazolam 1 mg/mL 90
1 Amiodarone HCl 5 mg/mL 90
16 Amitriptyline HCl 10 mg/mL 90
2 Amlodipine (as besylate) 1 mg/mL 90 1 mg/mL 60 Atenolol3 5 mg/mL 90
20 Atropine sulfate 0.1 mg/mL 90
29 Azathioprine 50 mg/mL 14 2 mg/mL 90 Baclofen21, 28 10 mg/mL 90
17 Caffeine 10 mg/mL 90
4 Captopril 0.8 mg/mL 14
16 Carbamazepine 25 mg/mL 90 1 mg/mL 90 Carvedilol16, 28 5 mg/mL 90
22 Celecoxib (capsules) 10 mg/mL 90
22 Chloral hydrate 100 mg/mL 60
2 Chloroquine phosphate 15 mg/mL 90
5 Cholecalciferol (vit. D3) 50,000 IU/mL 90
22 Ciprofloxacin HCI 50 mg/mL 90 / 60
17 Clomipramine HCl 5 mg/mL 90
3 Clonazepam 0.2 mg/mL 90
29 Clonidine HCl 0.1 mg/mL 90
29 Clopidogrel (as bisulfate, tablets) 5 mg/mL 30
, 23 Cloxacillin (capsules)* 50 mg/mL 5 Cyanocobalamine (vit. B12) 0.2 mg/mL 90
22 Cyclosporin 100 mg/mL 90
2 Dapsone 2 mg/mL 90
3 Dexamethasone 1 mg/mL 90
3 Diclofenac sodium 5 mg/mL 90
3 Diltiazem HCl 12 mg/mL 90
21 Dipyridamole 10 mg/mL 90
Compatible combination Combination not recommended 2-8 oC 15-25 oC Storage temperature
SyrSpend� SF Compatibility table Fagron SyrSpend� SF Compatibility table
SyrSpend� SF SyrSpend� SF SyrSpend� SF PH4 Liquid PH4 Dry ALKA Dry (PRESERVED) (UNPRESERVED) (UNPRESERVED)
Physical and Physical Physical Active pharmaceutical Ingredient (API) Concentration chemical Storage and chemical and chemical Storage stability (days) stability (days) stability (days)
16 Domperidone 5 mg/mL 90
3 Enalapril maleate 1 mg/mL 90 Esomeprazole magnesium**, 18 3 mg/mL 60
29 Ethambutol 2 HCl** (tablets) 50 mg/mL 30 50 mg/mL 90 Ethambutol 2 HCl**, 29 100 mg/mL 90
22 Flecainide acetate (tablets) 20 mg/mL 90
17 Folic acid 1 mg/mL 90 Furosemide1 10 mg/mL 14
6 Gabapentin 50 mg/mL 90 / 125
20 Glutamine 250 mg/mL 90
22 Glycopyrrolate (glycopyrronium bromide) 0.5 mg/mL 90
29 Griseofulvin 25 mg/mL 90
5 Haloperidol 0.5 mg/mL 90
29 Hydralazine HCl 4 mg/mL 30 2 mg/mL 90 Hydrochlorothiazide17, 28 5 mg/mL 90
22 Hydrocortisone 1 mg/mL 90
1 Hydrocortisone hemisuccinate 2 mg/mL 60
1 Hydrocortisone sodium phosphate 2 mg/mL 60
5 Imipramine HCl 5 mg/mL 90
16 Isoniazid 10 mg/mL 90
22 Itraconazole 20 mg/mL 90
16 Ketoconazole 20 mg/mL 90
3 Ketoprofen 20 mg/mL 90
22 Labetalol HCl (tablets) 40 mg/mL 90
3 Lamotrigine 1 mg/mL 90 Lansoprazole18 2 mg/mL
5 Levodopa and carbidopa 5 / 1.25 mg/mL 60 / 30
20 Levofloxacin 50 mg/mL 90
16 Lisinopril (as dihydrate) 1 mg/mL 90
17 Loperamide HCl 1 mg/mL 90
5 Lorazepam 1 mg/mL 90 / 60
21 Mebeverine HCl 10 mg/mL 90
22 Melatonin 3 mg/mL 90
Compatible combination Combination not recommended 2-8 oC 15-25 oC Storage temperature
Fagron SyrSpend� SF Compatibility table SyrSpend� SF Compatibility table
SyrSpend� SF SyrSpend� SF SyrSpend� SF PH4 Liquid PH4 Dry ALKA Dry (PRESERVED) (UNPRESERVED) (UNPRESERVED)
Physical and Physical Physical Active pharmaceutical Ingredient (API) Concentration chemical Storage and chemical and chemical Storage stability (days) stability (days) stability (days)
28 Mercaptopurine 10 mg/mL 90
28 Methadone HCl 10 mg/mL 90
17 Methotrexate 2.5 mg/mL 90
20 Metoprolol tartrate 10 mg/mL 90
7 Metronidazole benzoate 80 mg/mL 716 / 366
8, 19 Midazolam (as HCl, injection fluid) 1 mg/mL 60
5 Minocycline HCl 10 mg/mL 60
17 Nadolol 10 mg/mL 90
17 Naltrexone HCl 1 mg/mL 90
16 Naproxen 25 mg/mL 90
1 Nifedipine 4 mg/mL 90 Nitrendipine (tablets)*, 24 5 mg/mL 60
2 mg/mL 90 Nitrofurantoin20, 29 10 mg/mL 90 2 mg/mL 60 Omeprazole**, 9, 18 5 mg/mL 60
Ondansetron HCl 0.8 mg/mL 90 6 mg/mL 90 Oseltamivir (as phosphate, capsules)10, 19, 28 15 mg/mL 90
20 Oxandrolone 3 mg/mL 90 Pantoprazole sodium**, 18 3 mg/mL 60
16 Paracetamol (acetaminophen) 50 mg/mL 90
3 Penicillamine 50 mg/mL 90
17 Pentoxiphylline 20 mg/mL 90 9 mg/mL 90 / 154 Phenobarbital1, 28 15 mg/mL 90
2 Phenytoin 15 mg/mL 90 Prednisone*, 25 5 mg/mL 60
1 Prednisolone sodium phosphate 1.5 mg/mL 30
20 Pregabalin 20 mg/mL 90 0.5 mg/mL 90 Propranolol HCl11, 19, 28 1 mg/mL 146
5 mg/mL 90
21 Propylthiouracil 5 mg/mL 90 Pyrazinamide*, 26, 28 100 mg/mL 90
Compatible combination Combination not recommended 2-8 oC 15-25 oC Storage temperature
SyrSpend� SF Compatibility table Fagron SyrSpend� SF Compatibility table
SyrSpend� SF SyrSpend� SF SyrSpend� SF PH4 Liquid PH4 Dry ALKA Dry (PRESERVED) (UNPRESERVED) (UNPRESERVED)
Physical and Physical Physical Active pharmaceutical Ingredient (API) Concentration chemical Storage and chemical and chemical Storage stability (days) stability (days) stability (days)
2 Pyridoxine HCl (vit. B6) 50 mg/mL 90
21 Quinidine sulfate 10 mg/mL 90 Rabeprazole18 3 mg/mL
1 Ranitidine HCl 14 mg/mL 58 / 36
20 Riboflavin (vit. B2) 10 mg/mL 90
12 Rifampin (rifampicin) 25 mg/mL 60
16 Sertraline HCl 10 mg/mL 90 Sildenafil citrate 2.5 mg/mL 90
1 Simvastatin 1 mg/mL 90
28 Sotalol HCl (tablets) 5 mg/mL 90 2.0 mg/mL 90
1, 28 Spironolactone 2.5 mg/mL 90 25 mg/mL 90
22 Spironolactone and hydrochlorothiazide 5/5 mg/mL 90
2 Sulfadiazine 100 mg/mL 90
2 Sulfasalazine 100 mg/mL 90 1 mg/mL 90 Tacrolimus (as monohydrate)5, 28 0.5 mg/mL 90
5 Terbinafine HCl 25 mg/mL 90
2 Tetracycline HCI 25 mg/mL 90
3 Thiamine HCl (vit. B1) 100 mg/mL 90
29 Thioguanine 2.5 mg/mL 90
22 Tiagabine HCI (tablets) 1 mg/mL 90 / 30
21 Topiramate 5 mg/mL 90
5 Tramadol HCl 10 mg/mL 90
2 Trimethoprim 10 mg/mL 90 20 mg/mL 90 Ursodiol (ursodeoxycholic acid)13, 28 30 mg/mL 66
5 Valsartan 4 mg/mL 90 25 mg/mL 90 Vancomycin HCl14, 28 50 mg/mL 90
15 Verapamil HCl 50 mg/mL 60
, 27 Warfarin sodium (tablets)* 1 mg/mL 44 / 10
2 Zonisamide 10 mg/mL 90
Compatible combination Combination not recommended 2-8 oC 15-25 oC Storage temperature
Fagron SyrSpend� SF Compatibility table * Study performed by independent scientific working groups without Fagron Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), supervision. For a full list of all references, please be referred to: www.fagron. and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. Int J com/en/external-study-overview. Pharm Compd. 2016;20:426-434. ** Use raw pharmaceutical material for the API when compounding. 17. Polonini HC, Silva SL, de Almeida TR, Brandão MAF and Ferreira AO. Compat- ibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydro- References chlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone 1. Geiger CM, Sorenson B, Whaley P. Stability Assessment of 10 Active Phar- hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur J maceutical Ingredients Compounded in SyrSpend SF. Int J Pharm Compd. Hosp Pharm. 2016 (Published Online First). 2015;19:420-7. 18. Polonini HC, Silva SL, Loures S, Almy R, Balland A, Brandão MAF and Ferreira 2. Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MA, Raposo NR. Fea- AO. Compatibility of proton pump inhibitors in a preservative-free suspend- sibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, ing vehicle. Eur J Hosp Pharm 2016;0:1-7. pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochlo- 19. Dijkers ECF, Nanhekhan V, Thorissen A. Updated Stability Data of Midazolam, ride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Pharm Biomed Anal 2016;118:105-112. Minoxidil in Espumil. Int J Pharm Compd. 2017;21:240-241. 3. Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MAF. Stability of Aten- 20. Ferreira AO, Polonini HC, Loures da Silva S, Cerqueira de Melo VA, de An- olol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril drade L and Brandão MAF. Stability of Alprazolam, Atropine Sulfate, Gluta- Maleate, Ketoprofen, Lamotrigine, Penicillamine-D and Thiamine in SyrSpend mine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydro- SF PH4 Oral Suspensions. Int J Pharm Compd. 2016;20:167-174. chloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral 4. Geiger CM, Sorenson B, Whaley PA. Stability of Captopril in SyrSpend SF. Int Suspensions. Int J Pharm Compd. 2017;21:255-263. J Pharm Compd. 2013;17:336-338. 21. Polonini HC, Loures da Silva S, Buzinari Aglio NC, Abreu J, Brandão MAF and 5. Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of Ferreira AO. Stability of Acetazolamide, Baclofen, Dipyridamole, Mebevarine cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Sus- lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbina- pensions in SyrSpend SF PH4. Int J Pharm Compd. 2017;21:339-346. fine, tramadol hydrochloride, valsartan in SyrSpend® SF PH4 oral suspen- 22. Uriel M, Gómez-Rincón C, Marro, D. Stability of regularly prescribed oral liq- sions. Pharmazie. 2016;71:185-91. uids formulated with SyrSpend® SF. Die Pharmazie. 2018; 73:196-201. 6. Sorenson B, Voudrie MA, Gehrig D. Stability of Gabapentin in SyrSpend SF. 23. Barbazan C, Le Daré B, Lester MA and Boivin PN. Etude de stabilité d’une Int J Pharm Compd. 2012;16:347-349. suspension buvable de cloxacilline à usage pédiatrique. Poster presentation 7. Vu NT, Aloumanis V, Ben MJ, Kupiec TC, Patterson EK, Radke J, Erickson MA, at 11th Rencontres Convergences Santé Hôpital 2016. Schneider G. Stability of Metronidazole Benzoate in SyrSpend SF One-step 24. Bellay R, Lesourd F, Quilliec C, Gicquel T, Boivin PN and Lester MA. Stabilité Suspension System. Int J Pharm Compd. 2008;12:558-564. dúne suspension buvable de nitrendipine 5 mg/mL. Poster presentation at 8. Geiger CM, Sorenson B, Whaley PA. Stability of Midazolam in SyrSpend SF 11th Rencontres Convergences Santé Hôpital 2016. and SyrSpend SF Cherry. Int J Pharm Compd. 2013;17:344-346. 25. Bonnaure AC, Bellay R, Rault P, Lester MA and Boivin PN. Stability study of 5 9. Whaley PA, Voudrie MA, Sorenson B. Stability of Omeprazole in SyrSpend SF mg/ml pediatric prednisone oral suspension in Syrspend®. 20th European Alka (Reconstituted). Int J Pharm Compd. 2012;16:164-166. GERPAC Conference 2017. 10. Voudrie MA, Allen B. Stability of Oseltamivir Phosphate in SyrSpend SF, 26. Boivin P, Geffroy C, Tron C, et al PP-054 Stability study of 100 mg/ml paediat- Cherry Syrup and SyrSpend SF (For Reconstitution). Int J Pharm Compd. ric pyrazinamide oral suspension in syrspend. Eur J Hosp Pharm 2017;24:A225. 2010;14:82-85. 27. Guillois G, Fetique L, Perovic I, et al PP-028 Stability study of 1 mg/ml paedi- 11. Geiger CM, Voudrie MA, Sorensen B. Stability of Propranolol Hydrochloride atric warfarin oral suspension in syrspend. Eur J Hosp Pharm 2017;24:A214. in SyrSpend SF. Int J Pharm Compd. 2012;16:513-515. 28. Polonini H, da Silva SL, Brandão MAF, Bauters T, De Moerloose B, Ferreira AO. 12. Sorenson B, Whaley P. Stability of Rifampin in SyrSpend SF. Int J Pharm Com- Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, pd. 2013;17:162-164. Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propran- 13. Geiger CM, Voudrie MA, Sorenson B. Stability of Ursodiol in SyrSpend SF olol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Cherry Flavored. Int J Pharm Compd. 2012;16:510-512. Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydro- 14. Whaley PA, Voudrie MA. Stability of Vancomycin in SyrSpend SF. Int J Pharm chloride Oral Suspensions Compounded with SyrSpend SF pH4. Int J Pharm Compd. 2012;16:167-169. Compd. 2018 Nov-Dec;22(6):516-526. 15. Voudrie MA, Alexander B, Allen B. Stability of Verapamil Hydrochloride in Syr- 29. Polonini H, da Silva SL, de Araújo EP, Ferreira AO, Anagnostou K, Dijkers ECF. Spend SF compared to Sorbitol containing syrup and suspending vehicles. Stability of Azathioprine, Clonidine hydrochloride, Clopidogrel bisulfate, Int J Pharm Compd. 2011;15:255-258. Ethambutol hydrochloride, Griseofulvin, Hydralazine hydrochloride, Nitrofu- 16. Polonini HC, Loures S, de Araujo ED, Brandão MAF and Ferreira AO. Stability rantoin and Thioguanine oral suspensions compounded with SyrSpend® SF of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, PH4. Submitted for publication.
Disclaimer
Disclaimer: While a great deal of effort has been made to ensure the accuracy of the information contained herein, no claims are made as to the uses, safety, efficacy, or bioavailability of these recommendations. The information cannot be construed as (medical) advice, recommendation, or opinion. Health professionals us- ing this information are advised to do so solely if appropriate in their own professional opinion and judgment. Fagron does not accept and cannot be held responsible or liable in any case for the information contained herein.
Fagron BV Lichtenauerlaan 182 T +31 88 33 11 288 3062 ME Rotterdam F +31 88 33 11 210 The Netherlands www.fagron.com